Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Biopharma Company Issues New Patent Application; Phase 3 Clinical Trials for Cancer Treatments: RenovoRx (NASDAQ: RNXT) einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers Further clinical development planned